Morphoceuticals
Meisam Bagheri, Ph.D., currently serves in Translational R&D at Morphoceuticals, Inc. since December 2023 and has been affiliated with the Geisel School of Medicine at Dartmouth as a Research Scientist since November 2018. Expertise includes molecular oncology and drug discovery, with achievements in conceptualizing and leading in vivo tumor studies focused on Epithelial-Mesenchymal Plasticity and managing interdisciplinary research teams in in vivo rodent studies on protein kinase A mechanisms. Meisam has published research on novel drug targets related to breast cancer and has extensive experience in cell therapy, specifically in researching mesenchymal and dendritic cells to combat multiple sclerosis during a tenure as a Research Assistant at Shiraz University of Medical Sciences. Academic credentials include a Ph.D. in Molecular Genetics from the Indian Institute of Science and an MSc in Medical Genetics from the University of Madras.
This person is not in any teams
This person is not in any offices
Morphoceuticals
Morphoceuticals Inc. is a biotechnology company co-founded by Drs. Levin and Kaplan and funded by Juvenescence Ltd. Morphoceuticals is pioneering bioelectric approaches to access anatomical programming that is a core component of our biological operating system. Using proprietary combinations of ion channel and gap junction modulators, we are focused on inducing limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.